EFTA Document EFTA01457561

11 May 2016 Pharmaceuticals GlaxoSmithKline Performance review charts 'Figure 6: Quarterly and annual Core EPS growth (CER, %) 15 10 - 5 - 0 -to - -15 - 9 9 7 I 01 2 ; 4 .5 - -g -11 Ca N NCI CV IV e) 9R2g92289Rg99 -12 el Ir O LT LS -18 • — .3 .2 4 — N Cl 0 )- )- )- )- Li. LL LL LL Sane 0•4.0d0 ant aneenynil• Figure 7: Pharma CER growth rates 10% 5% , 0% -10% •15% 8% 2% -1% 2% -3% -3% 4% -3% -316 .4% -5% 4% • 3 94 NCVNNnelne100000 P.R999ggq9ggq9g999 I Pan Oantb, (tint Canon Ss 'Figure 8: Vaccines CER growth rates 20% t 14% 12% 10% " 10% 10% I a j 1%016 i 0%31 0% i I I al 41% -14% 18% •10% -20% I .30% -40% .50% 4 34_ N n N N CI e) e) NI a R 0 0 VI 92M9ggq9Rgq9R299 sew* Dome. bat an pony da 'Figure 10: Adyair CER growth rates 13% 1 8% 4%5% 2% 2%2% 2% 3% ar r e " 3% -1% 2% -2% -17% -22% 9% -1% 12953F -15% 44% -18% Cv N ea n f) t7 e) vr V • Le Yl P R RUM§ , AR§§RR§P Sane base* ark Ganasnaln Page 8 J 'Figure 9: Consumer CER growth rates 10% 8% 8% 4% O 2% cc w 0% 2% 4% 6% l! 4% 4% 5% —1 3.41 1 116 en$ ;ilk % 2i 4 I II 2% 3% -4% CV CV Cl N Cl Cl ri O •LT R Lf W9R2R9RRS9RRS9 Sown Accano ant Coroner 'Figure 1 t: New drug quarterly sales, £m 250 200 150 •I 100 50 1 I 4 158 0 3013 4013 1014 SIN icayfrourneg 2014 3014 'DB's* 4014 Nana° 1015 Sacra D_. Bank Cams,. dos 193 J Deutsche Bank AG/London CONFIDENTIAL — PURSUANT TO FED. R CRIM. P. 6(e) CONFIDENTIAL SDNY_GM_00283342 DB-SDNY-0117158 EFTA01457561